Total income from operation of the company declined by 25.52 per cent during the reported quarter at Rs 736.95 crore from Rs 989.59 crore in the corresponding period.Total consolidated income of the firm fell by 25 per cent to Rs 2,016.82 crore in the July-September quarter this fiscal from Rs 2,701.93 crore.-Subsequent to the September quarter, the company has sold certain fixed assets with carrying value of Rs 53.71 crore for Rs 11.46 crore.the company said its total standalone income rose by 9 per cent to Rs 1,739.15 crore in the quarter under review, as against Rs 1,603.06 crore.Commenting on SBI's sale of 3.9% stake in its life insurance venture SBI Life to private equity firms KKR and Temasek.The share of MCX jumped 8.7% to an intraday high of Rs 1413, seven rupees shy of its 52 week high hit on Oct 3, after news of Blackstone’s sale. The share closed up 2.5% at Rs 1332.5 on Friday.Recently, Sun Pharma announced that the US Food and Drug Administration had inspected the formulation facility between November 17 and December 1 and issued a Form 483.Non performing loans will likely rise as the company aligns norms to 90 days’ overdue.Big changes often start in small and inconspicuous ways, and it's entirely legitimate for the president to use his position to promote a broader shift in values.The Nifty50 moved in an extremely narrow range of 35 points before signing off the day with a 'Hanging Man' kind of formation ahead of the weekend.Shares of small companies ruled the roost on Friday, as the BSE Smallcap index surged 0.52 per cent as against a 0.20 gain in the benchmark BSE Sensex.Banking stocks were the second best performers of the day, thanks to a rise in the shares of ICICI Bank, SBI and Axis Bank.Wealth created is calculated in terms of change in market-cap of these cos during 2011-2016, duly adjusted for corporate events such as merger, de-merger.The committee of executive directors of the bank at its meeting held on Friday approved the proposed borrowing plan for the remaining period of financial year 2016-17.The architecture of NSE with respect to dissemination of Tick-by-Tick through Transmission Control Protocol or IP was prone to manipulation or market abuse.


Jul 24 2016 9:45PM

As per Derivatives data, it doesn’t look like Index can either cross 8600 level or retrace before the F&O expiry on 28th July.

Jul 11 2016 7:59PM

As per the prediction for July series, NIFTY Index is very near to upper level target of 8500. Watch this space for next update....

Jul 6 2016 6:40PM

Fitch downgrades india Banking Outlook to Negative


Weekly Market Alerts!!

NIFTY – Unlikely to give up on the gain before July F&O expiry    

24 Jul 2016

NIFTY – Unlikely to give up on the gain before July F&O expiry   

Technical & Derivatives Analysis: 24th July 2016


At the beginning of the series, I had given my prediction that NIFTY would trade in the range of 8000-8500 forJuly 2016. The results are in front of you. NIFTY is hovering around 8500 as we enter into F&O expiry week.

As you can see on the Technical chart, Index is trading near 76.4% Fibonacci Retracement level. It will be a turning point for NIFTY, if it is able to cross and sustain above this level.


As per Derivatives data, it doesn’t look like Index can either cross 8600 level or retrace before the F&O expiry on 28th July. Options IVs also does not indicate any big movement before expiry day. Best option would be to have little patience till expiry and then buckle your seat belt for the big move in August series. Keep close eye on Rollover number. I will provide next update immediately after expiry day…  

 Learn Technical & Derivatives Analysis | call 9892230682

NIFTY trading range for July'16 F&O Series : 8000-8500    

01 Jul 2016

NIFTY: 8000-8300 Consolidation Range for June 2016 F&O Series    

19 Jun 2016


To learn Practical Technical & Derivatives Analysis call 9892230682

Venue : Prabhadevi Dadar, Mumbai 25 Call@9892230682

18 Jun 2016

Disclaimer: All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Prior to execution of any security trade, you are advised to consult your authorized financial advisor to verify the accuracy of all information. Neither nor any independent provider is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.